Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma. At present, the treatment of new diagnosed AITL has limited efficacy and a high recurrence rate. The study seeks to explore the possibility of improving the efficacy of immunotherapy and chemotherapy and epigenetically regulated drugs.

Trial Details

NCT ID
NCT07168317
Phase
PHASE2
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • tislelizumab in combination with cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone
Locations (sample)
  • Xuzhou, Jiangsu, China|34.20442,117.28386

Key Eligibility Criteria

  • Pathological diagnosis of AITL according to WHO classification in 2016, and pathological diagnosis of AITL according to WHO classification in 2016,…
  • Never received systemic or local treatment including chemotherapy before;
  • Age ≥18 years old, male or female, ECOGPS≤3 points;
  • Life expectancy exceeds 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →